NCT07608549
FLASH Pilot Phase 1 Safety Study
At risk: Primary endpoint(s) modified.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary endpoint(s) modified
- Eligibility criteria expanded, about 16 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Incidences and grades of all grade-3-or-higher skin toxicities (according to CTCAE version 6.0) that are attributed to the electron FLASH treatment procedure [FLASH treatment safety and toxicity profile].
Timeframe: 5 years
Arms and interventions
Experimental arm treated with FLASH Radiation TherapyExperimental
In participants with more than one cutaneous lesion requiring treatment, one lesion will be treated with electron FLASH therapy. The prescription dose will be 8 Gray (Gy) in 1 fraction.
Control arm treated with Conventional Radiation TherapyActive comparator
In participants who have more than one cutaneous lesion requiring treatment, the remainder of the lesions not treated with electron FLASH therapy will be treated with conventional electron treatment at the discretion of the treating radiation oncologist.
Devices: IntraOp Mobetron UHDR
Radiation: Linac